[Acyclovir versus trifluorothymidine in the therapy of stromal herpes keratitis].
A randomized prospective double-blind trial with topical acyclovir (ACV) versus trifluorothymidine (TFT) was performed in the treatment of stromal keratitis. Resolution occurred in only one case (ACV). In all other cases the disease progressed, so that antiviral therapy was discontinued.
D000212:Acyclovir / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003319:Corneal Stroma / Q000187:drug effects; D003348:Cortisone / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013936:Thymidine / Q000031:analogs & derivatives*; D014271:Trifluridine / Q000627:therapeutic use*
D014271:Trifluridine; D003348:Cortisone; D013936:Thymidine; D000212:Acyclovir
Acyclovir versus Trifluorthymidin in der Therapie der stromalen Herpes-Keratitis.